ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 278-287

  Toquet, Claire ^a,b   Colson, Aude ^b   Jarry, Anne ^a   Bezieau, Stéphane ^a,b   Volteau, Christelle ^b   Boisseau, Pierre ^b   Merlin, Didier ^c   Laboisse, Christian L ^a,b   Mosnier, Jean François ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 1 integrin; ADAM15; colon carcinoma; epithelial to mesenchymal transition

Indexed keywords

ADAM 15 PROTEIN; ADAM PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 5;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CELL DIFFERENTIATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INTEGRIN ALPHA3BETA1; INTEGRIN ALPHA5BETA1; INTESTINAL MUCOSA; MALE; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 83655167108     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25891     Document Type: Article

References (40)

1. Weskamps G, Blobel CP,. A family of cellular proteins related to snake venom disintegrins. Proc Natl Acad Sci USA 1994; 91: 2748-51.
2. Wolfsberg TG, Straight PD, Gerena RL, Huovila AP, Primakoff P, Myles DG, White JM,. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995; 169: 378-83.
3. Black RA, White JM,. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998; 10: 654-9.
4. Gaultier A, Cousin H, Darribère T, Alfandari D,. ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. J Biol Chem 2002; 277: 23336-44.
5. Mochizuki S, Okada Y,. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98: 621-628.
6. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM,. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15: 1140-4.
7. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C,. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005; 26: 17-24.
8. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML,. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006; 8: 319-29.
9. Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, Fujita H, Nagai E, Tanaka M,. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007; 27: 793-9.
10. Najy AJ, Day KC, Day ML,. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 2008; 68: 1092-9.
11. Krätzschmar J, Lum L, Blobel CP,. Metargidin, a membrane-anchored metalloprotease- disintegrin protein with an RGD integrin binding sequence. J Biol Chem 1996; 271: 4593-6.
12. Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, Docherty AJ, Murphy G,. Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 1999; 112: 579-87.
13. Charrier L, Yan Y, Driss A, Laboisse CL, Sitaraman SV, Merlin D,. ADAM-15 inhibits wound healing in human intestinal epithelial cell monolayers. Am J Physiol 2005; 288: G346-53.
14. Charrier-Hisamuddin L, Laboisse CL, Merlin D,. ADAM-15: a metalloprotease that mediates inflammation. FASEB J 2008; 22: 641-53.
15. Mosnier JF, Jarry A, Bou-Hanna C, Denis MG, Merlin D, Laboisse CL,. ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Lab Invest 2006; 86: 1064-73.
16. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR,. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-35.
17. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER,. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 2001; 159: 2239-48.
18. Ogino S, Goel A,. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27.
19. Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumors. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press, 2000, 314 p.
20. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Lacopetta B, Hamelin R,. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002; 123: 1804-11.
21. Mason DY, Sammons RE,. The labeled antigen method of immunoenzymatic staining. J Histochem Cytochem 1979; 27: 832-40.
22. Kleino I, Ortiz RM, Yritys M, Huovila AP, Saksela K,. Alternative splicing of ADAM15 regulates its interactions with cellular SH3 proteins. J Cell Biochem 2009; 108: 877-85.
23. Kleino I, Ortiz RM, Huovila AP,. ADAM15 gene structure and differential alternative exon use in human tissues. BMC Mol Biol 2007; 8: 90.
24. Takai D, Jones PA,. The CpG island searcher: a new WWW resource. In Silico Biol 2003; 3: 235-40.
25. Takai D, Jones PA,. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002; 99: 3740-45.
26. Stallmach A, von Lampe B, Matthes H, Bornhöft G, Riecken EO,. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 1992; 33: 342-6.
27. Dogan A, Wang ZD, Spencer J,. E-cadherin expression in intestinal epithelium. J Clin Pathol 1995; 48, 143-6.
28. Ungerer C, Doberstein K, Bürger C, Hardt K, Boehncke WH, Böhm B, Pfeilschifter J, Dummer R, Mihic-Probst D, Gutwein P,. ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. Biochem Biophys Res Commun 2010; 401: 363-9.
29. Yang Y, Haitchi HM, Cakebread J, Sammut D, Harvey A, Powell RM, Holloway JW, Howarth P, Holgate ST, Davies DE,. Epigenetic mechanisms silence A Disintegrin And Metalloprotease 33 expression in bronchial epithelial cells. J Allergy Clin Immunol 2008; 121: 1393-9.
30. Mostafavi-Pour Z, Askari JA, Parkinson SJ, Parker PJ, Ng TT, Humphries MJ,. Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol 2003; 161: 155-67.
31. Zhang Z, Vuori K, Reed JC, Ruoslahti E,. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 1995; 92: 6161-5.
32. Gong J, Wang D, Sun L, Zborowska E, Willson JK, Brattain MG,. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997; 8: 83-90.
33. Camacho-Leal P, Zhai AB, Stanners CP,. A co-clustering model involving alpha5beta1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA). J Cell Physiol 2007; 211: 791-802.
34. Dieckgraefe BK, Santoro SA, Alpers DH,. Immunolocalization of alpha-integrin subunits and extracellular matrix components during human colonic organogenesis. Gastroenterology 1996; 110: 58-71.
35. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Brake M, Berx G,. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008; 130: 481-94.
36. Kreidberg JA,. Functions of alpha3beta1 integrin. Curr Opin Cell Biol 2000; 12: 548-53.
37. Sordat I, Bosman FT, Dorta G, Rousselle P, Aberdam D, Blum AL, Sordat B,. Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol 1998; 185: 44-52.
38. Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H, Reichmann E,. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005; 24: 2032-41.
39. Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, Terraciano L, Jass JR,. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumor budding in colorectal cancer. J Pathol 2007; 212: 260-8.
40. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G,. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5 beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008; 14: 7924-9.